查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1609454

慢性阻塞性肺病 (COPD) 治疗药市场评估:类型·药物类别·流通管道·各地区的机会及预测 (2018-2032年)

Chronic Obstructive Pulmonary Disease Treatment Market Assessment, By Type, By Drug Class, By Distribution Channel, By Region, Opportunities and Forecast, 2018-2032F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 248 Pages | 商品交期: 3-5个工作天内

价格

全球慢性阻塞性肺病 (COPD) 治疗药物市场规模预计将从 2024 年的 223.1 亿美元增长到 2032 年的 318.4 亿美元，预测期内复合年增长率为 4.55%。

人口快速老化、空气污染恶化、吸烟者数量不断增加是推动全球慢性阻塞性肺病（COPD）治疗市场需求的主要因素。慢性阻塞性肺病是一种通常同时涉及肺气肿和支气管炎的疾病，已知影响全世界数百万人。慢性阻塞性肺病的治疗通常包括皮质类固醇和吸入支气管扩张剂，以改善患者的生活品质和呼吸功能。治疗计划通常整合各种药物和非药物干预措施。

人口老化的快速扩大也支撑着市场的成长。世界卫生组织 (WHO) 估计，到 2030 年，全球六分之一的人口将超过 60 岁。这种成长正在推动该市场的需求，因为 60 岁以上人口的慢性阻塞性肺病盛行率是年轻人的两到三倍。此外，对患者依从性技术、数位疗法、先进治疗方法的投资不断增加，以及致力于个人化慢性阻塞性肺病治疗的生物製药公司数量不断增加，也为市场提供了利润丰厚的成长机会。

此外，市场领导者为确保 COPD 治疗和管理创新解决方案的可用性而做出的不懈努力，也为 COPD 治疗市场提供了利润丰厚的成长机会。全球医疗保健组织和政府机构还可以提高人们对慢性阻塞性肺病的认识，并利用各种治疗解决方案来应对日益严重的慢性阻塞性肺病威胁，并改善患者获得创新治疗的机会。

本报告提供全球慢性阻塞性肺病 (COPD) 治疗药的市场调查，彙整市场定义和概要，市场规模的转变·预测，各种区分·地区/各主要国家的详细分析，产业结构，影响市场成长因素的分析，案例研究，竞争情形，主要企业简介等资讯。

目录

第1章 计划的范围和定义

第2章 调查手法

第3章 摘要整理

第4章 全球慢性阻塞性肺病 (COPD) 治疗药市场展望

  • 市场规模的分析·预测
  • 市场占有率的分析·预测
    • 各类型
    • 各类药物
    • 各流通管道
    • 各地区
    • 企业占有率分析
  • 市场地图分析

第5章 北美慢性阻塞性肺病 (COPD) 治疗药市场展望

  • 市场规模的分析·预测
  • 市场占有率的分析·预测
  • 各国市场评估
    • 美国
    • 加拿大
    • 墨西哥

第6章 欧洲的慢性阻塞性肺病 (COPD) 治疗药市场展望

  • 德国
  • 法国
  • 义大利
  • 英国
  • 俄罗斯
  • 荷兰
  • 西班牙
  • 土耳其
  • 波兰

第7章 亚太地区的慢性阻塞性肺病 (COPD) 治疗药市场展望

  • 印度
  • 中国
  • 日本
  • 澳洲
  • 越南
  • 韩国
  • 印尼
  • 菲律宾

第8章 南美的慢性阻塞性肺病 (COPD) 治疗药市场展望

  • 巴西
  • 阿根廷

第9章 中东·非洲的慢性阻塞性肺病 (COPD) 治疗药市场展望

  • 沙乌地阿拉伯
  • UAE
  • 南非

第10章 供需分析

第11章 价值链分析

第12章 波特的五力分析

第13章 大环境分析

第14章 价格分析

第15章 市场动态

  • 推动市场要素
  • 市场课题

第16章 市场趋势·展开

第17章 相关法规·革新

第18章 专利形势

第19章 案例研究

第20章 竞争情形

  • 前五名公司的竞争矩阵
  • 前五名公司的SWOT分析
  • 前十大企业的形势
    • AstraZeneca PLC
    • Pfizer Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Novartis AG
    • F. Hoffmann-La Roche Ltd
    • Boehringer Ingelheim International GmbH
    • Sanofi S.A.
    • GlaxoSmithKline plc
    • Merck & Co., Inc.
    • Almirall, S.A.

第21章 策略性建议

第22章 关于本公司·免责声明

Product Code: MX12381

Global chronic obstructive pulmonary disease (COPD) treatment market is projected to witness a CAGR of 4.55% during the forecast period 2025-2032, growing from USD 22.31 billion in 2024 to USD 31.84 billion in 2032. The rapid expansion of the aging population, growing air pollution, and increasing popularity of smoking are some of the major factors bolstering the global chronic obstructive pulmonary disease (COPD) treatment market demand. The condition usually involves both emphysema and bronchitis and is known for affecting millions of individuals across the globe. The treatment for COPD usually involves corticosteroids and inhaled bronchodilators, among other therapies that improve the patients' quality of life and respiratory functioning. The treatment plans often integrate various pharmacologic and non-pharmacologic interventions.

The rapid expansion of the aging population also supports the market's growth. As per the estimates of the World Health Organization (WHO), one in six people across the globe will be sixty or older by 2030. This growth is bolstering the demand for the global chronic obstructive pulmonary disease (COPD) treatment market as the prevalence of the condition is two to three times higher in individuals over the age of sixty than in individuals from younger age groups. Furthermore, rising investments focused on patient adherence technologies, digital therapeutics, and advanced therapeutic approaches, coupled with an increasing number of biopharmaceutical companies working on personalized COPD treatment, also provide lucrative growth opportunities to the market.

Additionally, the dedicated efforts by the market's key players to ensure the availability of innovative solutions for treating and managing COPD also provide lucrative growth opportunities to the COPD treatment market. In May 2024, AstraZeneca PLC unveiled its latest research on immune-mediated and respiratory diseases at the American Thoracic Society (ATS) International Conference 2024. Meanwhile, healthcare organizations and government institutions across the globe are working on increasing awareness about COPD and the availability of different treatment solutions to address the growing threat of the disease and improve patient access to innovative therapies.

Increasing Approvals from Regulatory Bodies to Provide New Growth Opportunities

The different regulatory bodies across the globe are providing approval for various treatment solutions for COPD to aid patients suffering from uncontrolled COPD. In September 2024, the Medicines and Healthcare Products Agency (MHRA) authorized the usage of Dupilumab for treating uncontrolled COPD in the U.K. Dupilumab, a monoclonal antibody that inhibits the signaling of the interleukin-13 (IL13) and interleukin-4 (IL4) pathway, reduces type 2 inflammation observed in approximately 30-40% of patients with COPD. After receiving positive results from phase III clinical trials, the regulatory body has granted marketing authorization for subcutaneous injections as an add-on for maintenance treatment in adults with uncontrolled COPD.

Additionally, regulatory bodies increasingly provide accelerated approvals for novel treatment devices, drugs, and combination therapies to ensure patient access to advanced treatment solutions, driving innovation and positively influencing the market's expansion. Such approvals are essential as they aid in validating the efficacy and safety of the treatment solutions while fostering competition and allowing companies to introduce novel products.

Rising Research and Development Activities Support Market Expansion

The growing emphasis on research activities to bolster the availability of treatment solutions essential for treating COPD is a major global chronic obstructive pulmonary disease (COPD) treatment market driver. As the disease continues to impact millions across the globe, investments in research and development activities are rising to ensure the availability of effective treatment options. The multifaced research and development initiatives are targeting the development of innovative drugs, personalized medicines, and advanced inhalation devices to play a transformative role in managing COPD. For instance, in February 2024, ReAlta Life Sciences, Inc. initiated enrollment for the Phase II clinical trial of the RLS-0071 drug targeting acute exacerbations of COPD. The placebo-controlled, randomized, and double-blind trial assessed the pharmacokinetics, safety, efficacy, and pharmacokinetic-pharmacodynamic links of RLS-0071.

Additionally, the increasing collaborations between research institutions, healthcare providers, and pharmaceutical companies to address the complexities of COPD also provide lucrative growth opportunities to the market. Such partnerships and collaborations ensure cross-sector expertise sharing and support the development of advanced treatment solutions.

Hospital Pharmacies Account for Significant Market Share

Hospital pharmacies account for a significant share of the market owing to a wide range of factors, such as the unique dynamics of hospital settings and complex requirements for effective management of the condition. These pharmacies are essential for providing direct patient care to manage chronic health conditions such as COPD effectively. Pharmacists in these settings possess specialized knowledge and training in various respiratory medications, including combination therapies, corticosteroids, and bronchodilators. Furthermore, hospital pharmacies are equipped with a wide range of specialized formulations and advanced therapeutics which are often unavailable in retail pharmacies.

Additionally, hospital pharmacies across the globe are deploying technologically advanced solutions to facilitate efficient, safe, and accurate dispensing and management of drugs. As per the 2023 American Society of Health-System Pharmacists (ASHP) National Survey of Pharmacy Practice in Hospital Settings: Operations and Technology, approximately 73.6% of the hospitals surveyed utilize machine-readable coding for verifying doses during dispensing. Such efforts are also bolstering the segment's expansion.

North America is Anticipated to Hold a Major Market Share Over the Forecast Period

The expansion of the North America chronic obstructive pulmonary disease (COPD) treatment market can be attributed to the high acceptance and accessibility of novel diagnostic and treatment options and the strong presence of leading pharmaceutical companies in the region. Due to the rising prevalence of the condition in the region, the demand for effective treatment and management solutions is rising. According to the estimates of the Canadian Lung Association, over 2 million Canadians are affected by COPD, and it is one of the leading causes of hospitalization in Canada. The institute also estimates that there are approximately 1 million undiagnosed COPD population in the country.

The presence of different organizations, such as the American Association for Respiratory Care (AARC), that are dedicated to increasing awareness about lung health and treatment options available for various respiratory diseases, is also supporting the market's expansion. Furthermore, the strong presence of public and private healthcare systems in countries such as Canada and the United States is ensuring the affordability of COPD medication due to the widespread insurance coverage, bolstering the market's growth in North America.

Future Market Scenario (2024-2031F)

As per the global chronic obstructive pulmonary disease (COPD) treatment market analysis, the market is expected to witness significant growth in the coming years owing to the increasing efforts of the leading pharmaceutical companies to bolster the availability of novel therapies and the increasing prevalence of COPD. According to estimates from a modeling study published in the JAMA Network of the American Medical Association, by 2050, a relative growth of 23% in the number of patients with COPD will be witnessed compared to 2020.

Additionally, increasing government support and healthcare policy reforms across different regions are also expected to aid in addressing the cost-related challenges associated with COPD treatment, boosting patient access to the different treatment solutions. Innovative healthcare approaches, including precision medicine and digital healthcare solutions, are also anticipated to play a crucial role in COPD management and aid healthcare professionals in providing more effective and personalized treatment options. With the rise in investments in healthcare research and growing emphasis on developing innovative therapeutic solutions, the global chronic obstructive pulmonary disease (COPD) treatment market is expected to rapidly expand and aid patients in effectively managing the condition and improving their quality of life.

Key Players Landscape and Outlook

Key market players are actively investing in developing and introducing novel products in the market to aid patients suffering from COPD to manage the condition effectively. With the help of fast-track and breakthrough therapy designations for novel maintenance treatments for COPD, various regulatory bodies support such efforts. For instance, in August 2024, the Food and Drug Administration (FDA) granted breakthrough therapy designation as an add-on treatment for patients suffering from very severe to moderate COPD with a high blood count of eosinophils to AstraZeneca PLC and Amgen Inc.'s Tezspire. The primary intent of the breakthrough therapy designation is to provide interactive communications and timely advice to aid sponsors in conducting and designing drug development programs efficiently.

Similarly, in September 2024, Regeneron Pharmaceuticals, Inc. and Sanofi S.A.'s drug for treating COPD received approval from the FDA. Dupixent, the first biologic medicine approved in the United States for treating COPD, showed a 30% reduction in the annualized rate of COPD in a pair of Phase 3 studies. The drug had previously been approved for treating other conditions, such as asthma and atopic dermatitis. After receiving approval from the regulatory body, both companies witnessed a spike in their shares.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Outlook, 2018-2032F

  • 4.1. Market Size Analysis & Forecast
    • 4.1.1. By Value
  • 4.2. Market Share Analysis & Forecast
    • 4.2.1. By Type
      • 4.2.1.1. Emphysema
      • 4.2.1.2. Chronic Bronchitis
    • 4.2.2. By Drug Class
      • 4.2.2.1. Combination Therapy
      • 4.2.2.2. Bronchodilators
      • 4.2.2.3. Corticosteroids
      • 4.2.2.4. Phosphodiesterase Type 4 Inhibitor
      • 4.2.2.5. Mucokinetics
      • 4.2.2.6. Others
    • 4.2.3. By Distribution Channel
      • 4.2.3.1. Hospital Pharmacies
      • 4.2.3.2. Retail Pharmacies
      • 4.2.3.3. Online Pharmacies
    • 4.2.4. By Region
      • 4.2.4.1. North America
      • 4.2.4.2. Europe
      • 4.2.4.3. Asia-Pacific
      • 4.2.4.4. South America
      • 4.2.4.5. Middle East and Africa
    • 4.2.5. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
  • 4.3. Market Map Analysis, 2024
    • 4.3.1. By Type
    • 4.3.2. By Drug Class
    • 4.3.3. By Distribution Channel
    • 4.3.4. By Region

5. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Outlook, 2018-2032F*

  • 5.1. Market Size Analysis & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share Analysis & Forecast
    • 5.2.1. By Type
      • 5.2.1.1. Emphysema
      • 5.2.1.2. Chronic Bronchitis
    • 5.2.2. By Drug Class
      • 5.2.2.1. Combination Therapy
      • 5.2.2.2. Bronchodilators
      • 5.2.2.3. Corticosteroids
      • 5.2.2.4. Phosphodiesterase Type 4 Inhibitor
      • 5.2.2.5. Mucokinetics
      • 5.2.2.6. Others
    • 5.2.3. By Distribution Channel
      • 5.2.3.1. Hospital Pharmacies
      • 5.2.3.2. Retail Pharmacies
      • 5.2.3.3. Online Pharmacies
    • 5.2.4. By Country Share
      • 5.2.4.1. United States
      • 5.2.4.2. Canada
      • 5.2.4.3. Mexico
  • 5.3. Country Market Assessment
    • 5.3.1. United States Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Outlook, 2018-2032F*
      • 5.3.1.1. Market Size Analysis & Forecast
        • 5.3.1.1.1. By Value
      • 5.3.1.2. Market Share Analysis & Forecast
        • 5.3.1.2.1. By Type
          • 5.3.1.2.1.1. Emphysema
          • 5.3.1.2.1.2. Chronic Bronchitis
        • 5.3.1.2.2. By Drug Class
          • 5.3.1.2.2.1. Combination Therapy
          • 5.3.1.2.2.2. Bronchodilators
          • 5.3.1.2.2.3. Corticosteroids
          • 5.3.1.2.2.4. Phosphodiesterase Type 4 Inhibitor
          • 5.3.1.2.2.5. Mucokinetics
          • 5.3.1.2.2.6. Others
        • 5.3.1.2.3. By Distribution Channel
          • 5.3.1.2.3.1. Hospital Pharmacies
          • 5.3.1.2.3.2. Retail Pharmacies
          • 5.3.1.2.3.3. Online Pharmacies
    • 5.3.2. Canada
    • 5.3.3. Mexico

All segments will be provided for all regions and countries covered

6. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Outlook, 2018-2032F

  • 6.1. Germany
  • 6.2. France
  • 6.3. Italy
  • 6.4. United Kingdom
  • 6.5. Russia
  • 6.6. Netherlands
  • 6.7. Spain
  • 6.8. Poland

7. Asia-Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Outlook, 2018-2032F

  • 7.1. India
  • 7.2. China
  • 7.3. Japan
  • 7.4. Australia
  • 7.5. Vietnam
  • 7.6. South Korea
  • 7.7. Indonesia
  • 7.8. Philippines

8. South America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Outlook, 2018-2032F

  • 8.1. Brazil
  • 8.2. Argentina

9. Middle East and Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Outlook, 2018-2032F

  • 9.1. Saudi Arabia
  • 9.2. UAE
  • 9.3. South Africa
  • 9.4. Israel

10. Demand Supply Analysis

11. Value Chain Analysis

12. Porter's Five Forces Analysis

13. PESTLE Analysis

14. Pricing Analysis

15. Market Dynamics

  • 15.1. Market Drivers
  • 15.2. Market Challenges

16. Market Trends and Developments

17. Regulatory Framework and Innovation

  • 17.1. Clinical Trials
  • 17.2. Regulatory Approvals

18. Patent Landscape

19. Case Studies

20. Competitive Landscape

  • 20.1. Competition Matrix of Top 5 Market Leaders
  • 20.2. SWOT Analysis for Top 5 Players
  • 20.3. Key Players Landscape for Top 10 Market Players
    • 20.3.1. AstraZeneca PLC
      • 20.3.1.1. Company Details
      • 20.3.1.2. Key Management Personnel
      • 20.3.1.3. Products and Services
      • 20.3.1.4. Financials (As Reported)
      • 20.3.1.5. Key Market Focus and Geographical Presence
      • 20.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisitions
    • 20.3.2. Pfizer Inc.
    • 20.3.3. Teva Pharmaceutical Industries Ltd.
    • 20.3.4. Novartis AG
    • 20.3.5. F. Hoffmann-La Roche Ltd
    • 20.3.6. Boehringer Ingelheim International GmbH
    • 20.3.7. Sanofi S.A.
    • 20.3.8. GlaxoSmithKline plc
    • 20.3.9. Merck & Co., Inc.
    • 20.3.10. Almirall, S.A.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

21. Strategic Recommendations

22. About Us and Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 2. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Type, 2018-2032F
  • Figure 3. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 4. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 5. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Region, 2018-2032F
  • Figure 6. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 7. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Type, 2018-2032F
  • Figure 8. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 9. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 10. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Country, 2018-2032F
  • Figure 11. United States Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 12. United States Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Type, 2018-2032F
  • Figure 13. United States Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 14. United States Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 15. Canada Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 16. Canada Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Type, 2018-2032F
  • Figure 17. Canada Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 18. Canada Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 19. Mexico Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 20. Mexico Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Type, 2018-2032F
  • Figure 21. Mexico Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 22. Mexico Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 23. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 24. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Type, 2018-2032F
  • Figure 25. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 26. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 27. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Country, 2018-2032F
  • Figure 28. Germany Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 29. Germany Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Type, 2018-2032F
  • Figure 30. Germany Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 31. Germany Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 32. France Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 33. France Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Type, 2018-2032F
  • Figure 34. France Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 35. France Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 36. Italy Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 37. Italy Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Type, 2018-2032F
  • Figure 38. Italy Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 39. Italy Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 40. United Kingdom Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 41. United Kingdom Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Type, 2018-2032F
  • Figure 42. United Kingdom Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 43. United Kingdom Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 44. Russia Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 45. Russia Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Type, 2018-2032F
  • Figure 46. Russia Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 47. Russia Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 48. Netherlands Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 49. Netherlands Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Type, 2018-2032F
  • Figure 50. Netherlands Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 51. Netherlands Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 52. Spain Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 53. Spain Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Type, 2018-2032F
  • Figure 54. Spain Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 55. Spain Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 56. Turkey Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 57. Turkey Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Type, 2018-2032F
  • Figure 58. Turkey Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 59. Turkey Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 60. Poland Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 61. Poland Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Type, 2018-2032F
  • Figure 62. Poland Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 63. Poland Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 64. South America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 65. South America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Type, 2018-2032F
  • Figure 66. South America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 67. South America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 68. South America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Country, 2018-2032F
  • Figure 69. Brazil Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 70. Brazil Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Type, 2018-2032F
  • Figure 71. Brazil Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 72. Brazil Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 73. Argentina Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 74. Argentina Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Type, 2018-2032F
  • Figure 75. Argentina Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 76. Argentina Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 77. Asia-Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 78. Asia-Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Type, 2018-2032F
  • Figure 79. Asia-Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 80. Asia-Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 81. Asia-Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Country, 2018-2032F
  • Figure 82. India Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 83. India Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Type, 2018-2032F
  • Figure 84. India Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 85. India Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 86. China Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 87. China Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Type, 2018-2032F
  • Figure 88. China Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 89. China Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 90. Japan Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 91. Japan Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Type, 2018-2032F
  • Figure 92. Japan Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 93. Japan Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 94. Australia Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 95. Australia Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Type, 2018-2032F
  • Figure 96. Australia Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 97. Australia Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 98. Vietnam Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 99. Vietnam Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Type, 2018-2032F
  • Figure 100. Vietnam Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 101. Vietnam Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 102. South Korea Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 103. South Korea Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Type, 2018-2032F
  • Figure 104. South Korea Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 105. South Korea Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 106. Indonesia Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 107. Indonesia Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Type, 2018-2032F
  • Figure 108. Indonesia Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 109. Indonesia Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 110. Philippines Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 111. Philippines Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Type, 2018-2032F
  • Figure 112. Philippines Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 113. Philippines Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 114. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 115. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Type, 2018-2032F
  • Figure 116. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 117. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 118. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Country, 2018-2032F
  • Figure 119. Saudi Arabia Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 120. Saudi Arabia Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Type, 2018-2032F
  • Figure 121. Saudi Arabia Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 122. Saudi Arabia Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 123. UAE Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 124. UAE Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Type, 2018-2032F
  • Figure 125. UAE Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 126. UAE Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 127. South Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 128. South Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Type, 2018-2032F
  • Figure 129. South Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 130. South Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 131. By Type Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 132. By Drug Class Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 133. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 134. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2024